Mologen AG: Presentation On IMPACT Study At ESMO Symposium On Immuno-Oncology
Berlin, November 17, 2014 – MOLOGEN, a biotechnology company, announced today that data on long-term treated metastatic colorectal cancer patients from the IMPACT study will be presented at the ESMO Symposium on Immuno-Oncology 2014. The Symposium will take place on November 21-22 in Geneva.
IMPACT was a randomized placebo-controlled phase II trial with the cancer immune therapy MGN1703 in metastatic colorectal cancer.
Prof. Dr. Werner Scheithauer, Clinical Division of Oncology, Department of Medicine I, University Hospital in Vienna, Austria, one of the coordinating investigators of the IMPACT trial, will present the data in his lecture at the “Best Abstracts Session”.
Abstract details:
Title: Long-term maintenance therapy with the TLR-9 agonist MGN1703 in a subgroup of metastatic colorectal cancer patients from the IMPACT study.
Best Abstracts Session: November 21, 2014 at 5.25 pm – 6.45 pm.
The abstract will be published in the ESMO Symposium on Immuno-Oncology 2014 Abstract Book, a supplement to the official ESMO journal Annals of Oncology.
For more information on the ESMO please visit ESMO’s website: http://www.esmo.org/Conferences/Immuno-Oncology-2014.
For more information on the IMPACT trial please visit www.clinicaltrials.gov.
About IMPACT
IMPACT (Immunomodulatory MGN1703 in Patients with Advanced Colorectal Carcinoma with Disease Control after Initial First-line Therapy) was a phase II, randomized, placebo-controlled, double-blind, multicenter clinical study aiming to determine the efficacy of MGN1703 as switch maintenance therapy following first-line chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer.
Patients included in the IMPACT study had stabilization, or partial or complete remission of their disease after receiving first-line therapy for 4.5 to 6 months. The Patients were randomized to receive either MGN1703 or placebo twice per week. The treatment was continued until tumor progression was observed.
The primary endpoint of the study was to determine progression-free survival of the patients. Secondary study endpoints included overall survival, progression-free survival from start of induction therapy, response rates and safety, as well as collection of immunological and pharmacodynamic data.
About MGN1703
MGN1703 is an innovative DNA-based TLR-9 agonist developed by MOLOGEN. It broadly activates the immune system against tumor-associated antigens (TAA) which are released by cancer cells. Once activated by MGN1703, the immune system is able to overcome its fatal tolerance toward cancer cells and attacks them selectively. Due to this mechanism of action, MGN1703 can be applied to different indications of cancer.
MOLOGEN AG
MOLOGEN AG is a biotechnology company specialized in the research and clinical development of cancer immune therapies and DNA vaccines against infectious diseases.
The cancer immune therapy MGN1703 is the company’s lead product and best-in-class TLR-9 agonist. It is currently developed for first-line maintenance treatment of colorectal cancer (pivotal randomized trial) and lung cancer (randomized controlled trial). A second clinical-stage product is MGN1601, a therapeutic vaccination for the treatment of renal cancer. A phase I/II clinical study has already been completed successfully.
With unique, patented technologies and innovative products, MOLOGEN is pioneering immune therapies.
MOLOGEN AG is a publicly listed company, headquartered in Berlin. The shares (ISIN DE0006637200) are listed in the Prime Standard of the German Stock Exchange.
www.mologen.com
Memberships in associations:
Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V. | DECHEMA - Society for chemical technology and biotechnology e.V. | German industrial association of biotechnology (DIB) | Association for the Promotion of Science and Humanities in Germany | Association of German biotechnology companies (VBU) | Association of researching manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical industry e.V. (VCI)
MIDGE®, dSLIM®, EnanDIM® and MOLOGEN® are registered trademarks of MOLOGEN AG.
Contact
Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 – 86
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com
Help employers find you! Check out all the jobs and post your resume.
IMPACT was a randomized placebo-controlled phase II trial with the cancer immune therapy MGN1703 in metastatic colorectal cancer.
Prof. Dr. Werner Scheithauer, Clinical Division of Oncology, Department of Medicine I, University Hospital in Vienna, Austria, one of the coordinating investigators of the IMPACT trial, will present the data in his lecture at the “Best Abstracts Session”.
Abstract details:
Title: Long-term maintenance therapy with the TLR-9 agonist MGN1703 in a subgroup of metastatic colorectal cancer patients from the IMPACT study.
Best Abstracts Session: November 21, 2014 at 5.25 pm – 6.45 pm.
The abstract will be published in the ESMO Symposium on Immuno-Oncology 2014 Abstract Book, a supplement to the official ESMO journal Annals of Oncology.
For more information on the ESMO please visit ESMO’s website: http://www.esmo.org/Conferences/Immuno-Oncology-2014.
For more information on the IMPACT trial please visit www.clinicaltrials.gov.
About IMPACT
IMPACT (Immunomodulatory MGN1703 in Patients with Advanced Colorectal Carcinoma with Disease Control after Initial First-line Therapy) was a phase II, randomized, placebo-controlled, double-blind, multicenter clinical study aiming to determine the efficacy of MGN1703 as switch maintenance therapy following first-line chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer.
Patients included in the IMPACT study had stabilization, or partial or complete remission of their disease after receiving first-line therapy for 4.5 to 6 months. The Patients were randomized to receive either MGN1703 or placebo twice per week. The treatment was continued until tumor progression was observed.
The primary endpoint of the study was to determine progression-free survival of the patients. Secondary study endpoints included overall survival, progression-free survival from start of induction therapy, response rates and safety, as well as collection of immunological and pharmacodynamic data.
About MGN1703
MGN1703 is an innovative DNA-based TLR-9 agonist developed by MOLOGEN. It broadly activates the immune system against tumor-associated antigens (TAA) which are released by cancer cells. Once activated by MGN1703, the immune system is able to overcome its fatal tolerance toward cancer cells and attacks them selectively. Due to this mechanism of action, MGN1703 can be applied to different indications of cancer.
MOLOGEN AG
MOLOGEN AG is a biotechnology company specialized in the research and clinical development of cancer immune therapies and DNA vaccines against infectious diseases.
The cancer immune therapy MGN1703 is the company’s lead product and best-in-class TLR-9 agonist. It is currently developed for first-line maintenance treatment of colorectal cancer (pivotal randomized trial) and lung cancer (randomized controlled trial). A second clinical-stage product is MGN1601, a therapeutic vaccination for the treatment of renal cancer. A phase I/II clinical study has already been completed successfully.
With unique, patented technologies and innovative products, MOLOGEN is pioneering immune therapies.
MOLOGEN AG is a publicly listed company, headquartered in Berlin. The shares (ISIN DE0006637200) are listed in the Prime Standard of the German Stock Exchange.
www.mologen.com
Memberships in associations:
Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V. | DECHEMA - Society for chemical technology and biotechnology e.V. | German industrial association of biotechnology (DIB) | Association for the Promotion of Science and Humanities in Germany | Association of German biotechnology companies (VBU) | Association of researching manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical industry e.V. (VCI)
MIDGE®, dSLIM®, EnanDIM® and MOLOGEN® are registered trademarks of MOLOGEN AG.
Contact
Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 – 86
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com
Help employers find you! Check out all the jobs and post your resume.